Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 14/20 | 0.70 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | CTSV | O60911 | 1/20 | 0.52 |
| ▸ | ATP1A1 | P05023 | 2/20 | 0.51 |
| ▸ | ATP1B1 | P05026 | 2/20 | 0.51 |
| ▸ | ATP1A3 | P13637 | 2/20 | 0.51 |
| ▸ | ATP1B2 | P14415 | 2/20 | 0.51 |
| ▸ | ATP1A2 | P50993 | 2/20 | 0.51 |
| ▸ | ATP1B3 | P54709 | 2/20 | 0.51 |
| ▸ | FXYD2 | P54710 | 2/20 | 0.51 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 0.51 |
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31237298 | 0.89 | MAOA (0.70) | MAOAACHEMAOBEGFRCTSV | |
| SCHEMBL13589527 | 0.79 | MAOA (0.67) | MAOAACHEMAOBEGFRCTSV | |
| SCHEMBL27714097 | 0.78 | MAOA (0.70) | MAOAACHEMAOBCTSVMGAM | |
| SCHEMBL16244513 | 0.77 | MAOA (0.81) | MAOAACHEMAOBEGFRATP1A1 | |
| SCHEMBL29089940 | 0.77 | MAOA (0.69) | MAOAACHEMAOBEGFRATP1A1 | |
| SCHEMBL30513628 | 0.77 | MAOA (0.69) | MAOAACHEMAOBEGFRATP1A1 | |
| SCHEMBL8958340 | 0.77 | MAOA (0.74) | MAOAACHEMAOBEGFRATP1A1 | |
| SCHEMBL7228336 | 0.75 | ATP1A1 (0.79) | MAOAACHEMAOBEGFRATP1A1 | |
| SCHEMBL31238429 | 0.74 | MAOA (1.00) | MAOAACHEMAOBEGFRATP1A1 | |
| SCHEMBL31237273 | 0.74 | MAOA (1.00) | MAOAACHEMAOBEGFRATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824442-A1 | PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS DERIVED FROM GARCINIA MANGOSTANA L PLANT | Renaissance Herbs, Inc. (US) | 2007-08-29 | — | — | EP | claimed |
| WO-2007002666-A2 | PHARMACEUTICAL AND THERAPEUTIC COMPOSTIONS DERIVED FROM GARCINIA MANGOSTANA L PLANT | RENAISSANCE HERBS, INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060292255-A1 | Pharmaceutical and therapeutic compositions derived from Garcinia mangostana L plant | RENAISSSANCE HERBS INC. | 2006-12-28 | — | — | US | claimed |
| WO-2006055688-A1 | PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS DERIVED FROM GARCINIA MANGOSTANA L PLANT | RENAISSANCE HERBS, INC. (US) | 2006-05-26 | — | — | WO | claimed |
| US-20060105069-A1 | Pharmaceutical and therapeutic compositions derived from Garcinia mangostana L plant | RENAISSANCE HERBS, INC. | 2006-05-18 | — | — | US | claimed |
| EP-3763419-A1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Anji Pharma (US) LLC (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3110414-B1 | XANTHONE-RICH PLANT EXTRACTS OR COMPOUNDS THEREFROM FOR MODULATING DISEASES OF THE CENTRAL NERVOUS SYSTEM AND RELATED DISORDERS | UNIV DEAKIN (AU) | 2020-09-30 | — | — | EP | disclosed |
| EP-2661266-B1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ANJI PHARMA (US) LLC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | ANJI PHARMA (US) LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-10568862-B2 | Xanthone-rich plant extracts or compounds therefrom for modulating diseases of the central nervous system and related disorders | DEAKIN UNIVERSITY (AU) | 2020-02-25 | — | — | US | disclosed |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2019-02-07 | — | — | US | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| WO-2012094636-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011068814-A1 | ORAL COMPOSITIONS CONTAINING EXTRACTS OF GARCINIA MANGOSTANA L. AND RELATED METHODS | COLGATE-PALMOLIVE COMPANY (US) | 2011-06-09 | — | — | WO | disclosed |
| EP-1824442-A1 | PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS DERIVED FROM GARCINIA MANGOSTANA L PLANT | Renaissance Herbs, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| WO-2007002666-A2 | PHARMACEUTICAL AND THERAPEUTIC COMPOSTIONS DERIVED FROM GARCINIA MANGOSTANA L PLANT | RENAISSANCE HERBS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060292255-A1 | Pharmaceutical and therapeutic compositions derived from Garcinia mangostana L plant | RENAISSSANCE HERBS INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006055688-A1 | PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS DERIVED FROM GARCINIA MANGOSTANA L PLANT | RENAISSANCE HERBS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060105069-A1 | Pharmaceutical and therapeutic compositions derived from Garcinia mangostana L plant | RENAISSANCE HERBS, INC. | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568862-B2 | Xanthone-rich plant extracts or compounds therefrom for modulating diseases of the central nervous system and related disorders | GAP43, PMP22, ACHE | MAOA 373/4885ACHE 3/4885MAOB 420/4885 |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | MAOA 4424/4885ACHE 2757/4885MAOB 4142/4885 |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | TAS1R2, TAS2R1, GPR119 | MAOA 4424/4885ACHE 2757/4885MAOB 4142/4885 |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | MAOA 4424/4885ACHE 2757/4885MAOB 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.